- Oct 10, 1999
- 30,937
- 12,438
- 136
you mean the one that was retracted?Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines (nih.gov)
Data sources:
We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion.
Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Oh heres another:
Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients (nih.gov)
IVM used alone has been tested in more than 20 randomized, controlled trials (RCTs) for COVID-19 treatment, with statistically highly significant clinical benefits in almost all of these and an average of 62% reduction in risk of death
this is a better summary of what went on:
Ivermectin has been identified as an inexpensive, readily available drug with the potential to be repurposed as a treatment for COVID-19, especially in countries with limited access to vaccines. Although multiple studies have been published in an attempt to evaluate its usefulness in COVID-19, many are small and not constructed appropriately to detect differences in important clinical outcomes (ie, death). For this reason, researchers have turned to meta-analyses to combine study results and draw summary conclusions regarding ivermectin's effectiveness. Two such meta-analyses recently published in the American Journal of Therapeutics concluded that ivermectin decreased mortality and improved other surrogate end points in COVID-19.1–4 A recently withdrawn article caused both authors to rework their meta-analyses without altering their main conclusions.1–5 We feel that shortcomings within both sets of meta-analyses and limitations in the component studies are significant enough to invalidate their main finding that ivermectin reduces mortality. A review of other meta-analyses on the same subject, containing many of the same individual studies, were similarly limited by poor design.